Recently, leukemia induction following oncogene activation by randomly inserted replication-defective retroviral vectors has not only been seen in a mouse model, 1 but has subsequently also become clinical reality. 2 In order to define a therapeutic index of integrating vector systems, a number of studies have been initiated to estimate the actual risk of insertional mutagenesis for various gene therapy strategies. One important question to be answered relates to the impact of the number of integrated vector copies on the definitive mutagenic risk -theoretical considerations and experimental data for retroviral vectors indicate a linear relationship. [3] [4] [5] Based on this it seems reasonable to aim at restricting numbers of integrated (retroviral) vector copies. 5, 6 However, questions have been raised as to whether the data and suggestions recently reported for retroviral vectors based on murine leukemia virus (MLV) 6 may be applicable to other integrating vectors such as lentiviral, adeno-associated virus (AAV) or DNA transposase vectors. In fact, it would be important to know for any kind of vector how many copies per cell would be associated with a certain average transduction level in a target population. Mathematical approaches may help to answer this question.
To identify an appropriate mathematical model, one has to define conditions reflecting ex vivo transduction. First, for each transduction event one could assume that the resulting number of transduced cells is quite small (one), when compared to the number of cells in the preparation that could have been transduced. Consequently, the chance of a single cell to be transduced is also sufficiently small. Second, both the cell and vector preparations could be considered to be approximately homogeneous with respect to the transduction process. We can therefore assume that each cell in the preparation has the same chance to be transduced. In addition, we do not expect to find bystander effects during the transduction procedure, therefore we think that for each cell the chance of being transduced is independent of the transduction chance of any other cell. Under these circumstances, it seems appropriate to estimate the number of transduced cells in a preparation by means of Poisson's formula. 7 This formula gives us a strong tool to assess the distribution of rare, single events (such as the transduction of a single cell).
If the assumptions described above are fulfilled, the Poisson formula will hold, independent of the type of integrating vector or the way it enters the cell. Therefore, it could essentially be applicable for any ex vivo transduction protocol where isolated target cells (eg single cell suspensions) are transduced by homogenous vector preparations. In this case, the relative number of clones bearing a certain number of integrations may easily be predicted for a given transduction rate or mean copy number based on tables documenting the Poisson distribution. As one can see from Table 1 , from a statistical point of view more than one-tenth of the transduced cells are expected to have two or more (up to four) integrated vector copies even with a transduction rate as low as 22.1%; for 86.5% gene transfer with an average copy number of just two, one out of 1000 transduced clones may bear eight integrants. One important example fulfilling most criteria for using the Poisson formula (see below) would be the transduction of blood cells, for example, CD34-enriched hematopoietic stem cells or T lymphocytes, with retroviral vectors as in various ongoing clinical gene therapy protocols. 8, 9 The strength of the Poisson formula is also its weakness -it is 'just mathematics' and relies, as stated above, on the assumption of an equal probability for any cell to be infected. In reality, vectors may oligomerize, and target cells will differ regarding receptor expression or postreceptor defense mechanisms to viral entry. This is of special relevance for the transduction of mixed cell populations such as CD34-positive hematopoietic progenitor and stem cells. In such cases, for a given MOI the number of vector copies to be expected may be higher for the most susceptible subpopulation of progenitor cells as compared to more resistant primitive stem cells, thus introducing an additional level of complexity. Of note, theoretical considerations regarding the observed leukemia cases 1,2,5 as well as current analyses in a mouse model 10 suggest that the risk of oncogenic transformation after insertional mutagenesis may not only apply for true hematopoietic stem but also for these more susceptible progenitor cells. Importantly, in many clinical settings multiple transduction cycles are carried out to ensure sufficient gene transfer. Here, the fact of different susceptibility of target cells may become particularly problematic. In fact, the actual MOI for the cell fraction that will get transduced may be significantly higher than desired, resulting in more vector copies in transduced cells but lower transduction efficiencies than estimated based on the Poisson formula.
Still there is the question on the impact of higher copy numbers. The theoretical risk to hit and activate a proto-oncogene has recently been discussed for retroviral vectors in detail, 5 and could in principle be used as a paradigm for any integrating vector. This risk may obviously be lowered by decreasing the target cell number (eg using highly enriched stem cell) and by limiting the number of insertions. However, in the three published leukemia cases related to insertional mutagenesis, 1,2 a single insertion was present in the target cells, which led to the activation of proto-oncogenes (LMO-2, Evi-1). On the first view, this seems to contradict the broadly accepted rule that oncogenic transformation of primary cells requires up to six independent but cooperating genetic lesions. 11, 12 However, ectopic expression of receptor subunits (used as therapeutic or marker genes) has been proposed to have contributed to the malignant phenotypes ('second hit'). 1, 2, 13 It has also been suggested that the respective clones had to acquire additional mutations to become fully transformed, which corresponds to the long latency period of leukemia development. 1, 2, 13 Considering these data it might well be possible that more than one initial lesion during transduction is necessary in order to induce malignant transformation. This would, in part, explain the absence of similar observations of insertional oncogenesis in many other gene therapy and preclinical studies where nonsignaling genes were transferred. Moreover, if this assumption holds true, it strongly emphasizes the idea of avoiding multiple vector hits in single cells: given the risk of hitting one proto-oncogene may be in the range of 1 in 1.000 infused cells, 5 two hits into different such genes are quite probable for a transplant size as small as 10 million transduced cells (a small size even in the pediatric setting of X-SCID). 8 Consequently, induction of malignant transformation due to simultaneous activation of cooperating oncogenes may occur with quite a high probability, if multiple insertions are tolerated. Indeed, a recent work by Modlich et al 10 provides several examples of murine leukemias that resulted from multiple vector insertions leading to independent oncogeneactivating hits in one and the same hematopoietic progenitor cell clone.
In summary, integrating gene transfer vectors have been associated with potentially dangerous genetic lesions. To decrease the resulting potential risk, the number of vector insertions should be limited. Statistical methods as suggested here may be very useful as a general guide to predict insertion frequency distribution, but further experiments addressing this question for different vectors are strongly encouraged. Eventually, the oncogenic risk will have to be determined for each vector-transgene-host cell combination of interest. In the given idealized transduction model ((i) any cell has the same -very small -chance to be transduced; (ii) the transduction could be viewed as n independent transduction events, where n equals the -large -number of vector particles), the mean copy number (first column) would be equal to the multiplicity of infection ( 
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